X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9) 9
index medicus (9) 9
aged (8) 8
female (8) 8
middle aged (8) 8
male (7) 7
adult (5) 5
lymphomas (5) 5
pci-32765 (5) 5
protein-tyrosine kinases - antagonists & inhibitors (5) 5
leukemia (4) 4
oncology (4) 4
tyrosine (4) 4
abridged index medicus (3) 3
aged, 80 and over (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
article (3) 3
bruton's tyrosine kinase (3) 3
btk (3) 3
care and treatment (3) 3
chemotherapy (3) 3
chronic lymphocytic-leukemia (3) 3
clinical trials (3) 3
diarrhea (3) 3
disease-free survival (3) 3
drug therapy (3) 3
leukemia, lymphocytic, chronic, b-cell - drug therapy (3) 3
lymphocytosis (3) 3
lymphoma, mantle-cell - drug therapy (3) 3
medicine, general & internal (3) 3
pharmacology (3) 3
protein-tyrosine kinase (3) 3
pyrazoles - adverse effects (3) 3
pyrazoles - therapeutic use (3) 3
pyrimidines - adverse effects (3) 3
pyrimidines - therapeutic use (3) 3
recurrence (3) 3
tyrosine kinase inhibitor (3) 3
administration, oral (2) 2
agammaglobulinaemia tyrosine kinase (2) 2
analysis (2) 2
angiogenesis (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal - adverse effects (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - pharmacokinetics (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
chromosome 17 (2) 2
chromosome deletion (2) 2
chronic lymphatic leukemia (2) 2
clonal deletion (2) 2
cross-over studies (2) 2
diarrhea - chemically induced (2) 2
dosage and administration (2) 2
dose-response relationship, drug (2) 2
endothelial growth-factor (2) 2
fatigue (2) 2
hematology, oncology and palliative medicine (2) 2
ibrutinib (2) 2
indoles - adverse effects (2) 2
indoles - pharmacokinetics (2) 2
inhibitor drugs (2) 2
lymphatic leukemia (2) 2
lymphoma (2) 2
mantle cell lymphoma (2) 2
medicine & public health (2) 2
multikinase inhibitor (2) 2
nausea (2) 2
niacinamide - adverse effects (2) 2
niacinamide - analogs & derivatives (2) 2
niacinamide - pharmacokinetics (2) 2
patients (2) 2
pharmacokinetics (2) 2
pharmacology & pharmacy (2) 2
pharmacology/toxicology (2) 2
phase-ii (2) 2
product development (2) 2
protein kinase inhibitors - administration & dosage (2) 2
protein kinase inhibitors - adverse effects (2) 2
protein kinase inhibitors - pharmacokinetics (2) 2
protein kinase inhibitors - therapeutic use (2) 2
pyrazoles - administration & dosage (2) 2
pyrimidines - administration & dosage (2) 2
receptor (2) 2
safety (2) 2
signal transduction (2) 2
solid tumors (2) 2
therapeutic target (2) 2
therapy (2) 2
acquired-resistance (1) 1
activation (1) 1
adme (1) 1
androstadienes - administration & dosage (1) 1
androstadienes - adverse effects (1) 1
angiogenesis inhibitors - administration & dosage (1) 1
antacids (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - blood (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 3, pp. 228 - 235
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
B-CELL RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | IBRUTINIB | BTK | PCI-32765 | TYROSINE KINASE INHIBITOR | LYMPHOMA | OPEN-LABEL | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article
Nature Medicine, ISSN 1078-8956, 08/2015, Volume 21, Issue 8, pp. 922 - 926
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 6, pp. 507 - 516
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 3, pp. 213 - 223
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2015, Volume 75, Issue 1, pp. 111 - 121
Ibrutinib is an oral Bruton’s tyrosine kinase inhibitor, recently approved for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia... 
Nonlinear mixed effects model | Medicine & Public Health | ADME | Covariate analysis | Oncology | Cancer Research | Phase I–II | Pharmacology/Toxicology | Phase I-II | ONCOLOGY | THERAPEUTIC TARGET | PCI-32765 | BTK | PHARMACOLOGY & PHARMACY | Pyrazoles - therapeutic use | Pyrimidines - blood | Humans | Middle Aged | Half-Life | Biological Availability | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Intestinal Absorption | Dose-Response Relationship, Drug | Lymphoma, Mantle-Cell - blood | Pyrazoles - blood | Aged, 80 and over | Adult | Female | Leukemia, Lymphocytic, Chronic, B-Cell - blood | Antineoplastic Agents - pharmacokinetics | Pyrazoles - pharmacokinetics | Lymphoma, Mantle-Cell - metabolism | Protein Kinase Inhibitors - pharmacokinetics | Pyrimidines - administration & dosage | Food-Drug Interactions | Lymphoma, Mantle-Cell - drug therapy | Protein Kinase Inhibitors - blood | Cross-Over Studies | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Models, Biological | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Antineoplastic Agents - blood | Pyrimidines - pharmacokinetics | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Cohort Studies | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Care and treatment | Analysis | Leukemia | Phenols | Lymphomas | Models | Antacids
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 4168 - 4168
Background: Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) characterized by clonal stem cell proliferation of the erythroid, myeloid, and... 
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 2945 - 2945
Background: Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized by progressive bone marrow fibrosis, ineffective erythropoiesis, dysplastic... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. 4540 - 4540
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 156 - 156
Abstract Abstract 156 Background Bruton's tyrosine kinase (BTK) is a central mediator of B-cell receptor (BCR) signaling and is essential for normal B-cell... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2014, Volume 32, Issue 18_suppl, pp. LBA7008 - LBA7008
LBA7008 Background: Treatment options for CLL/ SLL patients (pts) who fail chemoimmunotherapy are limited. We report interim results from a phase III... 
Journal Article